Physician profile
Mark I Froimson
NPI 1386680213
$2,455,011.22
in general payments reported to CMS, 2019-2025
8 companies · $280K in 2025
The $280K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568K · 2020: $487K · 2021: $265K · 2022: $336K · 2023: $328K · 2024: $190K · 2025: $280K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $464K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $251K · Honoraria: $74K · Travel and Lodging: $5,877 · Food and Beverage: $3,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $463,755.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $251,380.65 |
| Honoraria | $74,000.00 |
| Travel and Lodging | $5,877.34 |
| Food and Beverage | $3,468.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $2,332,013.08 | 2019-2025 | Exparel, Iovera, Zilretta |
| Orthalign INC | $70,500.00 | 2019 | |
| Uoc USA INC | $36,873.42 | 2019-2020 | |
| Pacira Therapeutics, INC. | $14,000.00 | 2019 | |
| Smith+Nephew, INC. | $1,006.25 | 2019 | |
| Kci USA, INC. | $555.34 | 2019 | |
| Depuy Synthes Sales INC. | $63.13 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,155,465.13 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Froimson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.